Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering -- Mr. Silverman joins OncoSec with over two decades of...
OncoSec to Present at the Raymond James Human Health Innovation Conference PR Newswire PENNINGTON, N.J. and SAN DIEGO, May 27, 2021 PENNINGTON, N.J. and SAN DIEGO, May 27, 2021 /PRNewswire/...
OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management Biotech industry veteran brings over 20 years of project and alliance management experience largely...
OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma PR Newswire PENNINGTON, N.J. and SAN DIEGO, April 15, 2021 PENNINGTON...
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid Tumors -- CE mark enables commercialization of GenPulse™ in EU...
OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma Results From ILLUMINATE-301 To Be Discussed Webinar To Be Held on...
OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer -- TAVO intratumoral...
OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits Non-Dilutive Funding to Strengthen Balance Sheet PR Newswire PENNINGTON, N.J. and SAN DIEGO, Feb. 23, 2021 PENNINGTON...
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development Biotech industry veteran brings more than 15 years of clinical development and leadership experience largely...
OncoSec Strengthens Management Team With Two New Appointments PR Newswire PENNINGTON, N.J. and SAN DIEGO, Feb. 2, 2021 PENNINGTON, N.J. and SAN DIEGO, Feb. 2, 2021 /PRNewswire/ -- OncoSec Medical...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
